Q3 FY2025 · ended Sep 30, 2025 · Revenue $0 · Filed Nov 5, 2026
Inmune Bio Inc. (INMB) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Sep 30, 2026 it held $16.3 million in cash and investments and $1.2 million in total debt.
Revenue
$0
Net income
$-4.72M
+27.0% vs year-ago quarter
Operating cash flow
$-3.39M
+37.7% vs year-ago quarter
Free cash flow
$-3.09M
+45.2% vs prior quarter
EPS
$-0.17
+29.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
30.96M
+16.5% vs year-ago quarter
Net cash
$15.12M
Q3 FY2026
Operating margin
-19810.0%
Q1 FY2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Boca Raton, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1711754
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Operating income | -$5.0M | -$1.5M | -$5.8M | -$5.5M | -$7.4M |
| Net income | -$4.7M | -$1.3M | -$5.4M | -$5.3M | -$6.5M |
| Diluted EPS | -$0.17 | -$0.05 | -$0.20 | -$0.20 | -$0.24 |
| Operating cash flow | -$3.4M | -$3.2M | -$3.4M | -$2.9M | -$5.4M |
| Free cash flow | — | — | — | -$3.1M | -$5.6M |
| Total assets | $21.5M | $26.8M | $25.8M | $32.4M | $33.4M |
| Total liabilities | $3.4M | $6.5M | $6.2M | $8.8M | $8.0M |
| Stockholders' equity | $18.1M | $20.4M | $19.6M | $23.5M | $25.4M |
| Cash and investments | $16.3M | $18.4M | $21.4M | $24.8M | $27.7M |
| Total debt | $1.2M | $1.4M | $1.5M | $1.0M | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 29, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Sep 14, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 31, 2026 | Jul 31, 2026 |
All 601 Inmune Bio Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.